BUSH K; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. 1125.
Johnson & Johnson Pharm. Research & Development, Raritan, NJ.
Anti-infective Drug Discovery objectives in the 21st century continue to focus on the discovery and development of new antimicrobial agents that must be efficacious against infections caused by resistant organisms. As additional agents are introduced into the clinic, corresponding resistance mechanisms inevitably are selected, and the need for new drugs will persist. Surveillance studies repeatedly demonstrate that multidrug resistance is increasing in all the major pathogens, in spite of the new and potent agents that continue to be introduced. In addition, safety concerns with some of the established classes of agents such as the macrolides and recent fluoroquinolones encourage the development of agents with fewer side effects. Agents with more advantageous dosing regimens, such as oral administration or once-a-day dosing, may provide valuable medical benefits such as increased patient compliance and lower overall health care costs. Although unmet medical needs are the driving force, one cannot ignore the fact that cardiovascular, CNS and anti-infective agents represent the three largest therapeutic markets, based on total pharmaceutical sales. And, of these three areas, anti-infective agents that enter clinical trials have been shown to have the highest success rates for introduction into the marketplace. These commercial interests support the compelling medical and scientific rationales for continuing to identify new anti-infective agents.
Publication Types:
Keywords:
- Anti-Bacterial Agents
- Anti-Infective Agents
- Drug Resistance, Multiple
- Fluoroquinolones
- Humans
- Macrolides
- Streptococcus pneumoniae
Other ID:
UI: 102266507
From Meeting Abstracts